

23. A pharmaceutical composition, comprising:

(a) an immediate release dosage form containing a mixture of pharmaceutically active amphetamine salts; and

(b) a delayed release dosage form containing a mixture of pharmaceutically active amphetamine salts, said delayed release dosage form being selected from the group consisting of pH dependent and non-pH dependent dosage forms, said delayed release dosage form releasing said amphetamines within about 60 minutes after initiation of release of said amphetamines from the delayed release dosage form.

24. The pharmaceutical composition of claim 23 wherein the delayed release dosage form initiates release of amphetamines in from 4 to 6 hours after administration.

25. The composition of claim 23 wherein the delayed dose is a pH dependent delayed enteric dose.

26. The composition of claim 23 wherein the delayed dose is a pH independent delayed dose.

27. The composition of claim 23 wherein the composition includes an amount of amphetamines to provide an effective level thereof in a recipient without further administration over a course of eight hours. *for relief?*

28. The composition of claim 19 wherein the composition includes an amount of amphetamines to provide an effective level thereof in a recipient without further administration over a course of eight hours.

29. The composition of claim 19 wherein the delayed release dosage form releases said amphetamines within about 60 minutes after initiation of release of said amphetamines from the delayed release dosage form.

30. A process for treating ADHD, comprising:

treating ADHD by orally administering to a recipient a pharmaceutical comprising a mixture of pharmaceutically active amphetamine salts, said pharmaceutical containing an amount of said amphetamines to provide an effective level of the amphetamines in the recipient without further administration thereof over the course of eight hours, said pharmaceutical releasing said amphetamines as an immediate release dose and as a delayed release dose.

31. The process of claim 30 wherein, after release of the amphetamines from the delayed release dose, the plasma concentration of the amphetamines reaches a maximum level that is greater than the maximum level of the amphetamines plasma concentration that is reached during the period prior to release of amphetamines from the delayed release dose.

32. The process of claim 30 wherein the delayed release dose is a pH dependent delayed enteric dose.

33. The process of claim 30 wherein the delayed dose is a pH independent delayed dose.

34. The process of claim 30 wherein amphetamines of the delayed release dose are released within about sixty minutes after initiation of release of amphetamines from the delayed release dose.

35. The process of claim 30 wherein the pharmaceutical is in the form of a capsule, said capsule including the immediate release dose and the delayed release dose.

36. A process for treating ADHD, comprising:

treating ADHD by orally administering a pharmaceutical comprising a mixture of amphetamine salts, said pharmaceutical releasing said amphetamines in a first immediate release dose and a second delayed release dose, wherein after release of the amphetamines from the delayed release dose, the plasma concentration of the amphetamines reaches a maximum level that is greater than the maximum level of the

amphetamines plasma concentration that is reached during the period prior to release of amphetamines from the delayed release dose.

37. The process of claim 36 wherein the delayed dose is a pH dependent delayed enteric dose.

38. The process of claim 36 wherein the delayed dose is a pH independent delayed dose.

39. The process of claim 36 wherein amphetamines of the delayed release dose are released within about sixty minutes after initiation of release of amphetamines from the delayed release dose.

40. A process for treating ADHD, comprising treating ADHD by orally administering a pharmaceutical comprising a mixture of amphetamine salts, said pharmaceutical releasing the amphetamines in a first immediate release pulse and in a second delayed enteric pulse, said second delayed enteric pulse releasing said amphetamines within about 60 minutes after initiation of release of amphetamines from the delayed enteric pulse.

41. The process of claim 30 wherein the delayed dose is initiated in from 4 to 6 hours after administration.

42. The composition of claim 19 wherein the amphetamines are amphetamine bases.

43. The composition of claim 23 wherein the amphetamines are amphetamine bases.

44. The process of claim 30 wherein the amphetamines are amphetamine bases.

45. The process of claim 36 wherein the amphetamines are amphetamine bases.